Novel metabolic research update presenting experimental findings and outlining a biotech's next development steps, ideal for investors and scientists alike.
Key Takeaways
- MS 001 plus GLP-1 produced deeper weight loss without reducing caloric intake
- Combination therapy reduced weight regain after GLP-1 discontinuation in preclinical models
- Company plans a US$10 million Series A and targets initial clinical efficacy data in 2029